South Korea has agreed to buy 70,000 courses of Pfizer Inc's experimental antiviral Covid-19 pill, the Korea Disease Control and Prevention Agency has said, according to Reuters.

South Korea has already signed agreements to secure 200,000 courses of Merck & Co Inc's Covid-19 treatment. It is looking to buy an additional 134,000 courses, though it is undecided of which treatment, KDCA said.